| Followers | 54 |
| Posts | 6684 |
| Boards Moderated | 0 |
| Alias Born | 01/11/2017 |
Thursday, May 11, 2017 4:34:25 PM
When our company was sold, on closing day all outstanding shares were purchased by the new company. I'm certain we shareholders would "vote" on the deal but with Pears 240 shares, we won't have much say. If it is GILD, you'd "lose" the shares and get the money.
Sometimes they have options to convert to stock in the new company. So if you owned 100k shares and sold for $4 share, you'd get $400k or you may have the option to acquire $400k of GILD stock, which is ~$60/share. You would do that if you believed CYDY would elevate their stock price in the future however GILD is so large that even if PRO140 was a game changer, its only part of GILD's portfolio. They could screw up elsewhere.
Take the money and run- find another stock like PRO140 that you can play with with some of your profits. Notice I said $4/share because I don't think we are worth more than that. That is already 8x's today's price. I'd take 8x's right now. Even for those who bought at $1, it's still 4x!! Not bad!
Fingers crossed
Frip
Sometimes they have options to convert to stock in the new company. So if you owned 100k shares and sold for $4 share, you'd get $400k or you may have the option to acquire $400k of GILD stock, which is ~$60/share. You would do that if you believed CYDY would elevate their stock price in the future however GILD is so large that even if PRO140 was a game changer, its only part of GILD's portfolio. They could screw up elsewhere.
Take the money and run- find another stock like PRO140 that you can play with with some of your profits. Notice I said $4/share because I don't think we are worth more than that. That is already 8x's today's price. I'd take 8x's right now. Even for those who bought at $1, it's still 4x!! Not bad!
Fingers crossed
Frip
Recent CYDY News
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
